Our Rest of World segment is made up primarily of our operations in India, Japan and Australia. Also included are our operations in New Zealand and Emerging markets, which includes countries such as Brazil, China, Hong Kong, Malaysia, Taiwan and Thailand, in addition to Russia, South Africa and Turkey.
India is home to nearly half of Mylan’s workforce and approximately half of its manufacturing facilities. Moreover, about half of the company’s regulatory professionals and scientists are based in Hyderabad, where they work in one of Mylan’s global R&D centers. We also have a significant presence in Bangalore, which is where we have many injectables facilities and from which we manage our commercial activities, including our antiretroviral (ARV) and third-party active pharmaceutical ingredients businesses. Mylan’s robust commercial presence in India has made it the fastest growing multinational company in India with strong representation in therapeutic franchises such as hepatitis, oncology and critical care.
Since 2007, Mylan has been instrumental in increasing access to life-saving ARVs and has a majority market share in sub-Saharan African countries such as Zambia, Zimbabwe, Kenya, Nigeria and Cameroon. We are the number 1 provider of antiretroviral medicines in the developing world with a focus on Africa. Key to this achievement has been our success in introducing high quality USFDA-approved and WHO-prequalified products.
Mylan has been among the fastest growing companies in the Japan generics market for the last three years. We also maintain manufacturing capabilities in Japan, which play a key role in supplying our businesses throughout the country. Japan is the world’s second largest pharmaceutical market by value and the fourth largest generic prescription market by volume.
We hold leading positions in the generic pharmaceuticals markets in both Australia and New Zealand, in terms of volume.
With our recent acquisition of Meda, we have accelerated our expansion in attractive emerging markets, such as China, Russia, Southeast Asia and the Middle East.
- In Emerging markets, Mylan is the ARV market leader with more than 45% of the market share in terms of number of patients
- Mylan is the number 1 provider of Hepatitis C treatments in Southeast Asia
- Mylan has the number 1 branded medicine in the symptomatic slow acting drugs for osteoarthritis (SYSADOA) segment in Southeast Asia
- Mylan holds a leading share of the Hepatitis C market in India
- Number 1 supplier by volume to Australia's national pharmaceuticals program
- Produced more than 2 billion doses in Australia in 2016
- About 1 in 6 prescriptions dispensed in Australia is a Mylan product
We leverage a broad network of local and global access channels that include physicians, institutions, governments, retailers and wholesalers.
These are relationships we've built and nurtured over decades. Because trust goes beyond our global quality standards. It's all about caring for the people helped by what we do. That's how we treat our partners as well.
When you choose us as a partner, we make the relationship - and the shared value it creates - a priority. After all, it's important to us that you benefit from the work we do together.
If you dispense our difficult-to-manufacture and difficult-to-formulate products, you should know our commitment to producing them is long-term. Whether it's a medication for millions or for a handful of people, our priorities are to meet or exceed industry standards.